Positron Emission Tomography Market Report by Product Type, Detector Type, Application, End-User Countries and Company Analysis 2025–2033
Description
Positron Emission Tomography Market Size & Forecast 2025-2033
The Positron Emission Tomography (PET) market will grow from US$ 1.06 Billion in 2024 to US$ 1.51 Billion in 2033, at a Compound Annual Growth Rate (CAGR) of 4.02% from 2025–2033. Increased prevalence of chronic illnesses, technological advancements in imaging, and heightened demand for early and precise diagnostics drive growth. Increasing applications in oncology, neurology, and cardiology also drive worldwide market growth.
Positron Emission Tomography Market Outlook
Positron Emission Tomography (PET) is a sophisticated medical imaging modality that employs radioactive tracers to image metabolic processes and identify abnormalities within the body. Through the detailed 3D images of tissue and organ function, PET scans enable doctors to detect disease in its initial stages, even before structural changes are evident on conventional imaging techniques. The method is often used in conjunction with CT or MRI scans for accurate diagnosis.
Globally, PET is predominantly applied to detect and monitor cancer and to evaluate blood flow and cardiac function in cardiology, and to investigate brain disorders like Alzheimer's disease, epilepsy, and Parkinson's disease in neurology. Its popularity increases because of rising demand for early and precise diagnostics, minimally invasive treatments, and customized treatment planning.
The increasing number of chronic diseases worldwide, advancements in hybrid imaging technology, and favorable healthcare programs are fuelling growth. PET's capability to facilitate improved clinical decision-making makes it a key diagnostic tool in contemporary medicine in both developed and developing economies.
Growth Drivers in the Positron Emission Tomography Market
Rising Incidence of Chronic Diseases
The rising incidence of cancer, cardiovascular illnesses, and other types of neurological disorders has become a key growth driver in the positron emission tomography (PET) industry. Early diagnosis and accurate testing are critical in better managing these multifaceted health issues, and PET scans are unparalleled in imaging clarity compared to other diagnostic technologies. This new imaging technology allows physicians to image metabolic functions in real time, which enhances treatment decisions and ultimately patient outcomes. July 2024, Chronic kidney disease (CKD) impacts more than 35.5 million adults in the United States. The predominant causes of CKD in these individuals are diabetes and hypertension. Sadly, people are very much unaware of CKD; almost 9 out of 10 individuals suffering from the disease remain clueless. Even among severely affected CKD individuals, about 1 in 3 remains unaware of their condition.
Advancements in Imaging Systems
Hybrid imaging modalities like PET/CT and PET/MRI are transforming the landscape of medical diagnostics. These new technologies bring together various forms of imaging to provide a broader picture of physiological functions. Combined with major developments in detector technology, these modalities have the ability to create extremely clean and crisp images. Consequently, they are greatly enhancing diagnostic accuracy and allowing healthcare professionals to make better-informed decisions. This innovation wave is driving higher adoption at hospitals and diagnostic imaging centers, improving patient care and outcomes. Sep 2024, GE HealthCare was granted FDA clearance for Flyrcado™ (flurpiridaz F 18) injection, a new PET MPI agent to detect coronary artery disease (CAD). Targeted toward patients with suspected or known CAD, Flyrcado provides superior diagnostic performance compared with SPECT MPI, the dominant nuclear cardiology test. It can be manufactured offsite and shipped as a ready-to-use dose, which can enhance access to PET MPI and diagnostic precision, most notably for women and patients with high BMI.
Growing Applications in Personalized Medicine
With the healthcare environment increasingly moving towards precision and personalized medicine, there is a significant increase in the need for positron emission tomography (PET) imaging. This advanced imaging modality is vital in tracking therapy responses and optimal planning of treatment strategies in a patient-specific manner. Its unparalleled contribution towards validating whether therapies are working helps trigger worldwide market growth, promoting innovation and investment in this vital field of medical imaging. May 2022, Mediso Ltd has recently acquired Bartec Technologies Ltd, a UK-based specialist in supplying and supporting Nuclear Medicine and Molecular Imaging equipment and accessories.
Challenges in the Positron Emission Tomography Market
High Cost of PET Equipment and Procedures
PET scanners, as precious diagnostic tools in contemporary medicine, are burdened by enormous financial costs that acutely restrict their availability, especially in developing countries. The explosive cost of radiopharmaceuticals and the high operation and maintenance costs of these advanced imaging machines form insurmountable hurdles for healthcare facilities. This pecuniary burden frequently inhibits the capacity of hospitals and clinics in resource-poor regions to provide modern medical imaging, thereby ultimately affecting patient care and outcome.
Short Half-Life of Radioactive Tracers
Positron emission tomography (PET) scanning employs tracers with very short half-lives, which greatly restricts their potential for wider distribution. This reliance requires the close proximity of cyclotron facilities—where the tracers are manufactured—along with very efficient logistics operations to provide timely delivery. Consequently, this logistical difficulty presents considerable hindrances to universal access, especially in distant locations or areas of restricted resources, thus limiting the adoption and use of PET imaging technology in these areas.
Full-Ring Positron Emission Tomography Scanners Market
Full-ring PET scanners lead the market because they are very sensitive and can deliver complete 3D images. They are applied extensively in oncology, cardiology, and neurology fields. Full-ring models provide faster imaging times as well as better detection efficiency than partial-ring models. Rising hospital investments, expanding research in molecular imaging, and hybrid integration with imaging systems are driving demand for full-ring PET scanners across the globe.
Positron Emission Tomography Bismuth Germanium Oxide Market
BGO detectors find extensive applications in PET scanners due to their density and efficiency in detecting gamma-rays. While newer crystals such as LYSO are increasingly popular, BGO continues to be a trusted option for cost-saving PET solutions. The market enjoys increased installations in emerging nations and sustained demand for rugged and efficient detectors in oncology and neurology imaging applications.
Cardiology Positron Emission Tomography Market
Cardiology PET imaging is growing with the capability to evaluate myocardial perfusion, blood flow, and early diagnosis of coronary artery disease. PET scans are increasingly being favored for the assessment of heart function in high-risk patients, guidance for interventions, and evaluation of therapy progress. The increasing cardiovascular disease burden worldwide and increasing use of hybrid PET/CT systems within cardiology departments are driving growth in this segment.
Oncology Positron Emission Tomography Market
Oncology is the largest area for the PET market because detection and monitoring of cancer are still fundamental applications. PET scans facilitate early tumor detection, staging, and monitoring of therapy response to enhance treatment outcomes. With increased incidence of cancer and increasing applications in precision oncology, the demand for PET imaging is increasing internationally. Advances in radiopharmaceuticals and hybrid imaging modalities further reinforce its position in cancer treatment.
United States Positron Emission Tomography Market
The U.S. dominates the worldwide PET market because of superior healthcare infrastructure, elevated cancer incidence, and swift uptake of hybrid imaging technology. The availability of prime manufacturers, robust reimbursement schemes, and extensive research in radiopharmaceuticals fuel market growth. Ongoing investments in molecular imaging and clinical trials further establish the U.S. as a top hub for PET technology development and uptake. July 2024, Positrigo, a Swiss medical imaging specialist for nuclear medicine, has gained FDA clearance for its NeuroLF® brain PET system. The highly portable device supports the diagnosis and monitoring of brain diseases like Alzheimer's, brain tumors, epilepsy, and Parkinson's disease.
France Positron Emission Tomography Market
The PET market in France is supported by favorable government healthcare support and increasing focus on cancer and neurological diagnostics. Sophisticated hospitals and imaging centers in urban areas such as Paris and Lyon fuel the uptake of PET/CT systems. Interconnection with the European health network and investments in radiopharmaceutical production increase availability. Expanded application of PET in research, therapy monitoring, and early disease detection increases market growth. April 2025, Telix Pharmaceuticals reported that its prostate cancer imaging agent, Illuccix® (gallium-68 gozetotide injection), has been granted marketing authorization in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer.
China Positron Emission Tomography Market
China is witnessing strong PET market expansion driven by increasing incidence of cancer, urbanization, and growing healthcare infrastructure. Investments in government-funded nuclear medicine centers and local radiopharmaceutical manufacturing are enhancing accessibility. The market is aided by increasing demand for sophisticated diagnostic technologies in first-tier cities, while ongoing penetration into second-tier cities drives long-term opportunities in the PET imaging market. Jan. 2022, Clario and XingImaging have deepened their collaboration to perform PET imaging clinical trials of new therapeutics in China.
Brazil Positron Emission Tomography Market
Brazil's PET market is growing as a result of expanding awareness of the early detection of cancer and rising use of hybrid PET/CT imaging in urban hospital settings. Government and private investment in nuclear medicine equipment is enhancing diagnostic efficiencies. The market is challenged in terms of rural access but is aided by collaborations with global imaging firms and growing demand for cardiovascular and oncology imaging services.
Saudi Arabia Positron Emission Tomography Market
Saudi Arabia's PET market is underpinned by Vision 2030-driven healthcare modernization, emphasizing cutting-edge diagnostic tools. Financed investments in specialty hospitals and nuclear medicine are boosting PET uptake for oncology and cardiology use. Market accessibility is being enhanced through partnerships with global imaging firms and increased radiopharmaceutical manufacturing facilities. Medical tourism growth and increasing prevalence of chronic diseases are further driving demand. December 2024, King Abdulaziz University has launched the first diagnostic service for Alzheimer's disease, using combined positron emission tomography and magnetic resonance imaging, namely PET/MRI.
Market Segmentation
Product Type
• Full-Ring PET Scanners
• Partial-Ring PET Scanners
Detector Type
• Bismuth Germanium Oxide
• Lutetium Oxyorthosilicate
• Lutetium Fine Silicate
• Lutetium Yttrium Orthosilicate
• Gadolinium Oxyorthosilicate
Application
• Cardiology
• Neurology
• Oncology
• Others
End-User
• Hospitals and Clinics
• Diagnostic Centers
• Others
Country
North America
• United States
• Canada
Europe
• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey
Asia Pacific
• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand
Latin America
• Brazil
• Mexico
• Argentina
Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
All companies have been covered with 5 Viewpoints
• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis
Key Players Analysis
• Agfa Healthcare (Dedalus Group)
• GE Healthcare
• Koninklijke Philips NV
• Neusoft Medical Systems
• Positron Corporation
• Oncovision (Bruker)
• Mediso Medical Imaging Systems Ltd.
• Siemens Healthineers AG
• Segami Corporation
• Hitachi Ltd.
The Positron Emission Tomography (PET) market will grow from US$ 1.06 Billion in 2024 to US$ 1.51 Billion in 2033, at a Compound Annual Growth Rate (CAGR) of 4.02% from 2025–2033. Increased prevalence of chronic illnesses, technological advancements in imaging, and heightened demand for early and precise diagnostics drive growth. Increasing applications in oncology, neurology, and cardiology also drive worldwide market growth.
Positron Emission Tomography Market Outlook
Positron Emission Tomography (PET) is a sophisticated medical imaging modality that employs radioactive tracers to image metabolic processes and identify abnormalities within the body. Through the detailed 3D images of tissue and organ function, PET scans enable doctors to detect disease in its initial stages, even before structural changes are evident on conventional imaging techniques. The method is often used in conjunction with CT or MRI scans for accurate diagnosis.
Globally, PET is predominantly applied to detect and monitor cancer and to evaluate blood flow and cardiac function in cardiology, and to investigate brain disorders like Alzheimer's disease, epilepsy, and Parkinson's disease in neurology. Its popularity increases because of rising demand for early and precise diagnostics, minimally invasive treatments, and customized treatment planning.
The increasing number of chronic diseases worldwide, advancements in hybrid imaging technology, and favorable healthcare programs are fuelling growth. PET's capability to facilitate improved clinical decision-making makes it a key diagnostic tool in contemporary medicine in both developed and developing economies.
Growth Drivers in the Positron Emission Tomography Market
Rising Incidence of Chronic Diseases
The rising incidence of cancer, cardiovascular illnesses, and other types of neurological disorders has become a key growth driver in the positron emission tomography (PET) industry. Early diagnosis and accurate testing are critical in better managing these multifaceted health issues, and PET scans are unparalleled in imaging clarity compared to other diagnostic technologies. This new imaging technology allows physicians to image metabolic functions in real time, which enhances treatment decisions and ultimately patient outcomes. July 2024, Chronic kidney disease (CKD) impacts more than 35.5 million adults in the United States. The predominant causes of CKD in these individuals are diabetes and hypertension. Sadly, people are very much unaware of CKD; almost 9 out of 10 individuals suffering from the disease remain clueless. Even among severely affected CKD individuals, about 1 in 3 remains unaware of their condition.
Advancements in Imaging Systems
Hybrid imaging modalities like PET/CT and PET/MRI are transforming the landscape of medical diagnostics. These new technologies bring together various forms of imaging to provide a broader picture of physiological functions. Combined with major developments in detector technology, these modalities have the ability to create extremely clean and crisp images. Consequently, they are greatly enhancing diagnostic accuracy and allowing healthcare professionals to make better-informed decisions. This innovation wave is driving higher adoption at hospitals and diagnostic imaging centers, improving patient care and outcomes. Sep 2024, GE HealthCare was granted FDA clearance for Flyrcado™ (flurpiridaz F 18) injection, a new PET MPI agent to detect coronary artery disease (CAD). Targeted toward patients with suspected or known CAD, Flyrcado provides superior diagnostic performance compared with SPECT MPI, the dominant nuclear cardiology test. It can be manufactured offsite and shipped as a ready-to-use dose, which can enhance access to PET MPI and diagnostic precision, most notably for women and patients with high BMI.
Growing Applications in Personalized Medicine
With the healthcare environment increasingly moving towards precision and personalized medicine, there is a significant increase in the need for positron emission tomography (PET) imaging. This advanced imaging modality is vital in tracking therapy responses and optimal planning of treatment strategies in a patient-specific manner. Its unparalleled contribution towards validating whether therapies are working helps trigger worldwide market growth, promoting innovation and investment in this vital field of medical imaging. May 2022, Mediso Ltd has recently acquired Bartec Technologies Ltd, a UK-based specialist in supplying and supporting Nuclear Medicine and Molecular Imaging equipment and accessories.
Challenges in the Positron Emission Tomography Market
High Cost of PET Equipment and Procedures
PET scanners, as precious diagnostic tools in contemporary medicine, are burdened by enormous financial costs that acutely restrict their availability, especially in developing countries. The explosive cost of radiopharmaceuticals and the high operation and maintenance costs of these advanced imaging machines form insurmountable hurdles for healthcare facilities. This pecuniary burden frequently inhibits the capacity of hospitals and clinics in resource-poor regions to provide modern medical imaging, thereby ultimately affecting patient care and outcome.
Short Half-Life of Radioactive Tracers
Positron emission tomography (PET) scanning employs tracers with very short half-lives, which greatly restricts their potential for wider distribution. This reliance requires the close proximity of cyclotron facilities—where the tracers are manufactured—along with very efficient logistics operations to provide timely delivery. Consequently, this logistical difficulty presents considerable hindrances to universal access, especially in distant locations or areas of restricted resources, thus limiting the adoption and use of PET imaging technology in these areas.
Full-Ring Positron Emission Tomography Scanners Market
Full-ring PET scanners lead the market because they are very sensitive and can deliver complete 3D images. They are applied extensively in oncology, cardiology, and neurology fields. Full-ring models provide faster imaging times as well as better detection efficiency than partial-ring models. Rising hospital investments, expanding research in molecular imaging, and hybrid integration with imaging systems are driving demand for full-ring PET scanners across the globe.
Positron Emission Tomography Bismuth Germanium Oxide Market
BGO detectors find extensive applications in PET scanners due to their density and efficiency in detecting gamma-rays. While newer crystals such as LYSO are increasingly popular, BGO continues to be a trusted option for cost-saving PET solutions. The market enjoys increased installations in emerging nations and sustained demand for rugged and efficient detectors in oncology and neurology imaging applications.
Cardiology Positron Emission Tomography Market
Cardiology PET imaging is growing with the capability to evaluate myocardial perfusion, blood flow, and early diagnosis of coronary artery disease. PET scans are increasingly being favored for the assessment of heart function in high-risk patients, guidance for interventions, and evaluation of therapy progress. The increasing cardiovascular disease burden worldwide and increasing use of hybrid PET/CT systems within cardiology departments are driving growth in this segment.
Oncology Positron Emission Tomography Market
Oncology is the largest area for the PET market because detection and monitoring of cancer are still fundamental applications. PET scans facilitate early tumor detection, staging, and monitoring of therapy response to enhance treatment outcomes. With increased incidence of cancer and increasing applications in precision oncology, the demand for PET imaging is increasing internationally. Advances in radiopharmaceuticals and hybrid imaging modalities further reinforce its position in cancer treatment.
United States Positron Emission Tomography Market
The U.S. dominates the worldwide PET market because of superior healthcare infrastructure, elevated cancer incidence, and swift uptake of hybrid imaging technology. The availability of prime manufacturers, robust reimbursement schemes, and extensive research in radiopharmaceuticals fuel market growth. Ongoing investments in molecular imaging and clinical trials further establish the U.S. as a top hub for PET technology development and uptake. July 2024, Positrigo, a Swiss medical imaging specialist for nuclear medicine, has gained FDA clearance for its NeuroLF® brain PET system. The highly portable device supports the diagnosis and monitoring of brain diseases like Alzheimer's, brain tumors, epilepsy, and Parkinson's disease.
France Positron Emission Tomography Market
The PET market in France is supported by favorable government healthcare support and increasing focus on cancer and neurological diagnostics. Sophisticated hospitals and imaging centers in urban areas such as Paris and Lyon fuel the uptake of PET/CT systems. Interconnection with the European health network and investments in radiopharmaceutical production increase availability. Expanded application of PET in research, therapy monitoring, and early disease detection increases market growth. April 2025, Telix Pharmaceuticals reported that its prostate cancer imaging agent, Illuccix® (gallium-68 gozetotide injection), has been granted marketing authorization in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer.
China Positron Emission Tomography Market
China is witnessing strong PET market expansion driven by increasing incidence of cancer, urbanization, and growing healthcare infrastructure. Investments in government-funded nuclear medicine centers and local radiopharmaceutical manufacturing are enhancing accessibility. The market is aided by increasing demand for sophisticated diagnostic technologies in first-tier cities, while ongoing penetration into second-tier cities drives long-term opportunities in the PET imaging market. Jan. 2022, Clario and XingImaging have deepened their collaboration to perform PET imaging clinical trials of new therapeutics in China.
Brazil Positron Emission Tomography Market
Brazil's PET market is growing as a result of expanding awareness of the early detection of cancer and rising use of hybrid PET/CT imaging in urban hospital settings. Government and private investment in nuclear medicine equipment is enhancing diagnostic efficiencies. The market is challenged in terms of rural access but is aided by collaborations with global imaging firms and growing demand for cardiovascular and oncology imaging services.
Saudi Arabia Positron Emission Tomography Market
Saudi Arabia's PET market is underpinned by Vision 2030-driven healthcare modernization, emphasizing cutting-edge diagnostic tools. Financed investments in specialty hospitals and nuclear medicine are boosting PET uptake for oncology and cardiology use. Market accessibility is being enhanced through partnerships with global imaging firms and increased radiopharmaceutical manufacturing facilities. Medical tourism growth and increasing prevalence of chronic diseases are further driving demand. December 2024, King Abdulaziz University has launched the first diagnostic service for Alzheimer's disease, using combined positron emission tomography and magnetic resonance imaging, namely PET/MRI.
Market Segmentation
Product Type
• Full-Ring PET Scanners
• Partial-Ring PET Scanners
Detector Type
• Bismuth Germanium Oxide
• Lutetium Oxyorthosilicate
• Lutetium Fine Silicate
• Lutetium Yttrium Orthosilicate
• Gadolinium Oxyorthosilicate
Application
• Cardiology
• Neurology
• Oncology
• Others
End-User
• Hospitals and Clinics
• Diagnostic Centers
• Others
Country
North America
• United States
• Canada
Europe
• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey
Asia Pacific
• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand
Latin America
• Brazil
• Mexico
• Argentina
Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
All companies have been covered with 5 Viewpoints
• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis
Key Players Analysis
• Agfa Healthcare (Dedalus Group)
• GE Healthcare
• Koninklijke Philips NV
• Neusoft Medical Systems
• Positron Corporation
• Oncovision (Bruker)
• Mediso Medical Imaging Systems Ltd.
• Siemens Healthineers AG
• Segami Corporation
• Hitachi Ltd.
Table of Contents
200 Pages
- 1. Introduction
- 2. Research & Methodology
- 2.1 Data Source
- 2.1.1 Primary Sources
- 2.1.2 Secondary Sources
- 2.2 Research Approach
- 2.2.1 Top-Down Approach
- 2.2.2 Bottom-Up Approach
- 2.3 Forecast Projection Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 5. Global Positron Emission Tomography Market
- 5.1 Historical Market Trends
- 5.2 Market Forecast
- 6. Market Share Analysis
- 6.1 By Product Type
- 6.2 By Detector Type
- 6.3 By Application
- 6.4 By End-User
- 6.5 By Countries
- 7. Product Type
- 7.1 Full-Ring PET Scanners
- 7.1.1 Market Analysis
- 7.1.2 Market Size & Forecast
- 7.2 Partial-Ring PET Scanners
- 7.2.1 Market Analysis
- 7.2.2 Market Size & Forecast
- 8. Detector Type
- 8.1 Bismuth Germanium Oxide (BGO)
- 8.1.1 Market Analysis
- 8.1.2 Market Size & Forecast
- 8.2 Lutetium Oxyorthosilicate (LSO)
- 8.2.1 Market Analysis
- 8.2.2 Market Size & Forecast
- 8.3 Lutetium Fine Silicate (LFS)
- 8.3.1 Market Analysis
- 8.3.2 Market Size & Forecast
- 8.4 Lutetium Yttrium Orthosilicate (LYO)
- 8.4.1 Market Analysis
- 8.4.2 Market Size & Forecast
- 8.5 Gadolinium Oxyorthosilicate (GSO)
- 8.5.1 Market Analysis
- 8.5.2 Market Size & Forecast
- 9. Application
- 9.1 Cardiology
- 9.1.1 Market Analysis
- 9.1.2 Market Size & Forecast
- 9.2 Neurology
- 9.2.1 Market Analysis
- 9.2.2 Market Size & Forecast
- 9.3 Oncology
- 9.3.1 Market Analysis
- 9.3.2 Market Size & Forecast
- 9.4 Others
- 9.4.1 Market Analysis
- 9.4.2 Market Size & Forecast
- 10. End-User
- 10.1 Hospitals and Clinics
- 10.1.1 Market Analysis
- 10.1.2 Market Size & Forecast
- 10.2 Diagnostic Centers
- 10.2.1 Market Analysis
- 10.2.2 Market Size & Forecast
- 10.3 Others
- 10.3.1 Market Analysis
- 10.3.2 Market Size & Forecast
- 11. Countries
- 11.1 North America
- 11.1.1 United States
- 11.1.1.1 Market Analysis
- 11.1.1.2 Market Size & Forecast
- 11.1.2 Canada
- 11.1.2.1 Market Analysis
- 11.1.2.2 Market Size & Forecast
- 11.2 Europe
- 11.2.1 France
- 11.2.1.1 Market Analysis
- 11.2.1.2 Market Size & Forecast
- 11.2.2 Germany
- 11.2.2.1 Market Analysis
- 11.2.2.2 Market Size & Forecast
- 11.2.3 Italy
- 11.2.3.1 Market Analysis
- 11.2.3.2 Market Size & Forecast
- 11.2.4 Spain
- 11.2.4.1 Market Analysis
- 11.2.4.2 Market Size & Forecast
- 11.2.5 United Kingdom
- 11.2.5.1 Market Analysis
- 11.2.5.2 Market Size & Forecast
- 11.2.6 Belgium
- 11.2.6.1 Market Analysis
- 11.2.6.2 Market Size & Forecast
- 11.2.7 Netherlands
- 11.2.7.1 Market Analysis
- 11.2.7.2 Market Size & Forecast
- 11.2.8 Turkey
- 11.2.8.1 Market Analysis
- 11.2.8.2 Market Size & Forecast
- 11.3 Asia Pacific
- 11.3.1 China
- 11.3.1.1 Market Analysis
- 11.3.1.2 Market Size & Forecast
- 11.3.2 Japan
- 11.3.2.1 Market Analysis
- 11.3.2.2 Market Size & Forecast
- 11.3.3 India
- 11.3.3.1 Market Analysis
- 11.3.3.2 Market Size & Forecast
- 11.3.4 South Korea
- 11.3.4.1 Market Analysis
- 11.3.4.2 Market Size & Forecast
- 11.3.5 Thailand
- 11.3.5.1 Market Analysis
- 11.3.5.2 Market Size & Forecast
- 11.3.6 Malaysia
- 11.3.6.1 Market Analysis
- 11.3.6.2 Market Size & Forecast
- 11.3.7 Indonesia
- 11.3.7.1 Market Analysis
- 11.3.7.2 Market Size & Forecast
- 11.3.8 Australia
- 11.3.8.1 Market Analysis
- 11.3.8.2 Market Size & Forecast
- 11.3.9 New Zealand
- 11.3.9.1 Market Analysis
- 11.3.9.2 Market Size & Forecast
- 11.4 Latin America
- 11.4.1 Brazil
- 11.4.1.1 Market Analysis
- 11.4.1.2 Market Size & Forecast
- 11.4.2 Mexico
- 11.4.2.1 Market Analysis
- 11.4.2.2 Market Size & Forecast
- 11.4.3 Argentina
- 11.4.3.1 Market Analysis
- 11.4.3.2 Market Size & Forecast
- 11.5 Middle East & Africa
- 11.5.1 Saudi Arabia
- 11.5.1.1 Market Analysis
- 11.5.1.2 Market Size & Forecast
- 11.5.2 UAE
- 11.5.2.1 Market Analysis
- 11.5.2.2 Market Size & Forecast
- 11.5.3 South Africa
- 11.5.3.1 Market Analysis
- 11.5.3.2 Market Size & Forecast
- 12. Value Chain Analysis
- 13. Porter's Five Forces Analysis
- 13.1 Bargaining Power of Buyers
- 13.2 Bargaining Power of Suppliers
- 13.3 Degree of Competition
- 13.4 Threat of New Entrants
- 13.5 Threat of Substitutes
- 14. SWOT Analysis
- 14.1 Strength
- 14.2 Weakness
- 14.3 Opportunity
- 14.4 Threats
- 15. Pricing Benchmark Analysis
- 15.1 Agfa Healthcare (Dedalus Group)
- 15.2 GE Healthcare
- 15.3 Koninklijke Philips NV
- 15.4 Neusoft Medical Systems
- 15.5 Positron Corporation
- 15.6 Oncovision (Bruker)
- 15.7 Mediso Medical Imaging Systems Ltd.
- 15.8 Siemens Healthineers AG
- 15.9 Segami Corporation
- 15.10 Hitachi Ltd.
- 16. Key Players Analysis
- 16.1 Agfa Healthcare (Dedalus Group)
- 16.1.1 Overviews
- 16.1.2 Key Person
- 16.1.3 Recent Developments
- 16.1.4 SWOT Analysis
- 16.1.5 Revenue Analysis
- 16.2 GE Healthcare
- 16.2.1 Overviews
- 16.2.2 Key Person
- 16.2.3 Recent Developments
- 16.2.4 SWOT Analysis
- 16.2.5 Revenue Analysis
- 16.3 Koninklijke Philips NV
- 16.3.1 Overviews
- 16.3.2 Key Person
- 16.3.3 Recent Developments
- 16.3.4 SWOT Analysis
- 16.3.5 Revenue Analysis
- 16.4 Neusoft Medical Systems
- 16.4.1 Overviews
- 16.4.2 Key Person
- 16.4.3 Recent Developments
- 16.4.4 SWOT Analysis
- 16.4.5 Revenue Analysis
- 16.5 Positron Corporation
- 16.5.1 Overviews
- 16.5.2 Key Person
- 16.5.3 Recent Developments
- 16.5.4 SWOT Analysis
- 16.5.5 Revenue Analysis
- 16.6 Oncovision (Bruker)
- 16.6.1 Overviews
- 16.6.2 Key Person
- 16.6.3 Recent Developments
- 16.6.4 SWOT Analysis
- 16.6.5 Revenue Analysis
- 16.7 Mediso Medical Imaging Systems Ltd.
- 16.7.1 Overviews
- 16.7.2 Key Person
- 16.7.3 Recent Developments
- 16.7.4 SWOT Analysis
- 16.7.5 Revenue Analysis
- 16.8 Siemens Healthineers AG
- 16.8.1 Overviews
- 16.8.2 Key Person
- 16.8.3 Recent Developments
- 16.8.4 SWOT Analysis
- 16.8.5 Revenue Analysis
- 16.9 Segami Corporation
- 16.9.1 Overviews
- 16.9.2 Key Person
- 16.9.3 Recent Developments
- 16.9.4 SWOT Analysis
- 16.9.5 Revenue Analysis
- 16.10 Hitachi Ltd.
- 16.10.1 Overviews
- 16.10.2 Key Person
- 16.10.3 Recent Developments
- 16.10.4 SWOT Analysis
- 16.10.5 Revenue Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
